SCHEMBL3017308

SCHEMBL3017308

Cc1ccc(S(=O)(=O)N2CCN(c3nc(-c4cccc(C)c4C)cs3)CC2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.55
ALDH1A1 P00352 2/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
MAPT P10636 2/20 0.52
USP2 O75604 1/20 0.52
RECQL P46063 1/20 0.52
HSD17B10 Q99714 1/20 0.52
HSD11B1 P28845 2/20 0.50
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
LMNA P02545 2/20 0.47
MAPK1 P28482 2/20 0.47
CRHBP P24387 1/20 0.47
CRHR2 Q13324 1/20 0.47
GBA1 P04062 3/20 0.47
HDAC3 O15379 1/20 0.47
HDAC4 P56524 1/20 0.47
HDAC1 Q13547 1/20 0.47
HDAC7 Q8WUI4 1/20 0.47
HDAC2 Q92769 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3015386 0.92 SMN1; SMN2 (0.53) L3MBTL1ALDH1A1SMN1; SMN2MAPTUSP2
SCHEMBL3008137 0.92 SMN1; SMN2 (0.53) L3MBTL1ALDH1A1SMN1; SMN2MAPTUSP2
SCHEMBL3012413 0.92 ALDH1A1 (0.68) L3MBTL1ALDH1A1SMN1; SMN2MAPTUSP2
SCHEMBL3008014 0.91 L3MBTL1 (0.57) L3MBTL1ALDH1A1SMN1; SMN2MAPTUSP2
SCHEMBL3007848 0.90 HSD11B1 (0.54) L3MBTL1ALDH1A1SMN1; SMN2MAPTUSP2
SCHEMBL3017985 0.90 MAPT (0.61) L3MBTL1ALDH1A1SMN1; SMN2MAPTUSP2
SCHEMBL3011688 0.89 SMN1; SMN2 (0.51) L3MBTL1ALDH1A1SMN1; SMN2MAPTUSP2
SCHEMBL3014177 0.89 ALDH1A1 (0.51) L3MBTL1ALDH1A1SMN1; SMN2MAPTUSP2
SCHEMBL3014790 0.88 ALDH1A1 (0.58) L3MBTL1ALDH1A1SMN1; SMN2MAPTUSP2
SCHEMBL3014594 0.88 MAPT (0.49) L3MBTL1ALDH1A1SMN1; SMN2MAPTUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA L3MBTL1 1847/4885ALDH1A1 3510/4885SMN1; SMN2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.